Third Harmonic Bio Inc. (THRD)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Third Harmonic Bio Statistics
Share Statistics
Third Harmonic Bio has 45.06M shares outstanding. The number of shares has increased by 10.67% in one year.
Shares Outstanding | 45.06M |
Shares Change (YoY) | 10.67% |
Shares Change (QoQ) | 9.64% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 21.24M |
Failed to Deliver (FTD) Shares | 1.7K |
FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 3.52M, so 7.82% of the outstanding shares have been sold short.
Short Interest | 3.52M |
Short % of Shares Out | 7.82% |
Short % of Float | 21.01% |
Short Ratio (days to cover) | 14.23 |
Valuation Ratios
The PE ratio is -14.11 and the forward PE ratio is -3.64. Third Harmonic Bio 's PEG ratio is 0.75.
PE Ratio | -14.11 |
Forward PE | -3.64 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 1.62 |
P/FCF Ratio | -21.12 |
PEG Ratio | 0.75 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Third Harmonic Bio Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 50.29, with a Debt / Equity ratio of 0.01.
Current Ratio | 50.29 |
Quick Ratio | 50.29 |
Debt / Equity | 0.01 |
Total Debt / Capitalization | 1.45 |
Cash Flow / Debt | -5.17 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.11% and return on capital (ROIC) is -16.1%.
Return on Equity (ROE) | -0.11% |
Return on Assets (ROA) | -0.11% |
Return on Capital (ROIC) | -16.1% |
Revenue Per Employee | 0 |
Profits Per Employee | -604.39K |
Employee Count | 51 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -63.43% in the last 52 weeks. The beta is 2.67, so Third Harmonic Bio 's price volatility has been higher than the market average.
Beta | 2.67 |
52-Week Price Change | -63.43% |
50-Day Moving Average | 7.7 |
200-Day Moving Average | 11.51 |
Relative Strength Index (RSI) | 26.47 |
Average Volume (20 Days) | 574.62K |
Income Statement
Revenue | n/a |
Gross Profit | -35K |
Operating Income | -43.95M |
Net Income | -30.82M |
EBITDA | -30.79M |
EBIT | n/a |
Earnings Per Share (EPS) | -0.78 |
Balance Sheet
The company has 269.07M in cash and 3.95M in debt, giving a net cash position of 265.12M.
Cash & Cash Equivalents | 269.07M |
Total Debt | 3.95M |
Net Cash | 265.12M |
Retained Earnings | -114.22M |
Total Assets | 304.49M |
Working Capital | 293.17M |
Cash Flow
In the last 12 months, operating cash flow was -20.43M and capital expenditures -169K, giving a free cash flow of -20.59M.
Operating Cash Flow | -20.43M |
Capital Expenditures | -169K |
Free Cash Flow | -20.59M |
FCF Per Share | -0.52 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
THRD does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -21.79% |
FCF Yield | -12.75% |
Analyst Forecast
The average price target for THRD is $14, which is 291.1% higher than the current price. The consensus rating is "Hold".
Price Target | $14 |
Price Target Difference | 291.1% |
Analyst Consensus | Hold |
Analyst Count | 3 |
Scores
Altman Z-Score | 9.99 |
Piotroski F-Score | 3 |